aod9604 targets stubborn fat AOD 9604 Fat loss is more than

The same group showed NNMT inhibition simultaneously elevated both NAD+ and SAM in adipose tissue, suggesting a dual metabolic benefit mechanism of significant research interest

Researchers isolated this specific sequence because early work showed it retained growth hormones fat-burning properties without triggering the broader hormonal cascade that affects growth, blood sugar, and tissue development

One should not use AOD-9604 if they: Are pregnant or breastfeeding Are a minor Have a current or recent history of cancer (particularly hormone-sensitive cancers) Have uncontrolled diabetes or significant insulin resistance Have active thyroid disease that is not well-managed Are taking medications that may interact with peptide therapy (discuss with your provider) Have a known hypersensitivity to peptide compounds Comprehensive labs including metabolic panel, fasting glucose, HbA1c, thyroid panel, lipid panel, and hormone levels should be run before starting any peptide therapy and monitored regularly throughout

The MitoPrime peptide vial is the NAD+/MOTS-c/5-Amino-1MQ research product

These stubborn areas are characterized by several factors including high alpha-2 adrenergic receptor density relative to beta receptors, reduced blood flow, and greater insulin sensitivity leading to efficient fat storage

Your practitioner will advise on a suitable treatment plan following consultation